19 November 2026

Rosetrees backs next stage of research into promising new antibiotics for drug-resistant pneumonia

Rosetrees is delighted to continue supporting the work of Dr Ishwar Singh and his team at the University of Liverpool, who have secured over £1 million in funding to advance a promising new class of antibiotics targeting drug-resistant pneumonia.

Dr Ishwar Singh, Reader in Antimicrobial Drug Discovery at the University of Liverpool, has been awarded £1 million through PACE (Pathways to Antimicrobial Clinical Efficacy), a collaboration between Innovate UK, LifeArc and Medicines Discovery Catapult. Rosetrees is contributing a further £50,000 to support this important next stage of the research.

Together, this funding will help advance Novltex, a novel class of synthetic antibiotics being developed to tackle infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB).

Tackling a critical global health challenge

Antimicrobial resistance (AMR) is one of the most urgent threats to global health. As bacteria develop resistance to existing antibiotics, infections become increasingly difficult to treat, placing patients at greater risk and creating an urgent need for new treatments.

CRAB is a particularly concerning example. It can cause severe, life-threatening pneumonia in hospital patients, especially those requiring mechanical ventilation. The World Health Organisation identifies it as a critical priority for antibiotic development.

Despite the significant need for new treatments, no new antibiotic chemical class with activity against A. baumannii has reached patients in more than 50 years.

A promising new approach to antibiotic development

Developed by Dr Singh’s team at the University of Liverpool, Novltex represents a new chemical class of synthetic antibiotics. Laboratory studies have demonstrated activity against resistant bacterial strains, with encouraging results also seen in preclinical infection models.

The compounds work by targeting lipid II, an essential building block of the bacterial cell wall. By binding to lipid II, they disrupt the bacteria’s ability to construct and maintain this protective wall.

The team is investigating whether targeting this highly conserved component could make it more difficult for bacteria to develop resistance.

The next phase of the programme will focus on designing and testing improved versions of the most promising compounds. Researchers will investigate how to enhance their antibacterial activity and ensure that sufficient quantities of the antibiotic can reach the lungs and remain there long enough to treat infection.

Preclinical infection models will help establish the levels needed to control infection and identify which compounds should progress to further development.

Sustained support to advance medical research

Rosetrees has supported Dr Singh’s research over many years, helping to underpin the work that has led to this important development. Our additional £50,000 contribution will support the programme as it enters this next stage of development.

Our CEO, Ann Berger, said:

“Antimicrobial resistance is one of the most urgent threats to global health and Rosetrees has made it a key priority for funding. That is why we are delighted to have supported Dr Singh’s work for many years and to provide additional funding for this programme at this important stage. Dr Singh is working at speed to provide solutions, and we hope this will lead to patient benefit in the not too distant future.”

The PACE award will provide significant support to help the team progress Novltex towards further preclinical development. It also highlights the importance of collaboration between researchers, charities and organisations supporting the development of new medicines.

If future studies demonstrate that Novltex is safe and effective, it could offer a much-needed treatment option for patients with severe drug-resistant pneumonia, helping to reduce reliance on the limited antibiotics currently available.

Rosetrees is proud to continue supporting innovative research that has the potential to address major unmet medical needs and ultimately improve outcomes for patients.